



IFW

PATENT
017191.0049

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re U.S. Patent Application

Applicant: Michael J. Pugia

Serial No.: 10/574,862

Filed: April 6, 2006

For: **Monoclonal Antibodies for
Detection of Urinary Trypsin
Inhibitors**

) Customer No.: 47670

)

) I hereby certify that this correspondence is
) being deposited with the United Postal Service
) as Express Mail in an envelope addressed to:
) Mail Stop AMENDMENT, Commissioner of
) Patents, P. O. Box 1450, Alexandria, VA,
) 22313-1450, on May 25, 2006

)

Signature

人

1

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.97 and 1.98

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

In compliance with the duty of disclosure under 37 C.F.R. §1.56, it is respectfully requested that this Information Disclosure Statement be entered and the reference(s) listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.98(d), copies of the listed references are enclosed.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information disclosed is, or is considered to be, prior art with respect to the present application or material to patentability as defined in 37 C.F.R. §§ 1.56.

The present Information Disclosure Statement is being filed within three months of the filing date of this application and hence is believed to be timely in accordance with 37 C.F.R. § 1.97(b). Accordingly, no fees are believed to be due in connection with the filing of this Information Disclosure Statement. However, should any fees be deemed necessary (except payment of the issue fee), the Commissioner is authorized to charge any deficiency or to credit any overpayment to Kelley Drye & Warren LLP Account No. 11-0404/017191.0049.

Respectfully submitted,

5/25/06
Date

Harold N. Wells

Harold N. Wells
Reg. No. 26,044
Kelley Drye & Warren LLP
333 West Wacker Drive, Suite 2600
Chicago, IL 60606
(312) 857-2336
(312) 857-7095 (Fax)
Attorneys for Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/574,862		
		Filing Date	April 6, 2006		
		First Named Inventor	Michael J. Pugia		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	7	Attorney Docket Number	017191.0049

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		6,242,197	06/05/2001	Papuashvili	
		2001/0055816	12/27/2001	Rehm et al.	
		2002/0004219	01/10/2002	Corey et al.	
		6,583,108	06/24/2003	Tamburini et al.	
		2003/0125577	07/03/2003	Corey et al.	
		2003/0190732	10/09/2003	Josic	
		6,673,632	01/06/2004	Ohshiro	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		JP 10-70997	03/17/1998	Uenoyama et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Pugia et al.; "Pathophysiology and diagnostic value of urinary trypsin inhibitors," <i>Clin Chem Lab Med</i> , Vol. 43 (1), 2005, pp. 1-16.	
		Zhu et al.; "Analysis of ligand binding by bioaffinity mass spectrometry," <i>Clinica Chimica Acta</i> xx, (2006) xxx-xxx, CCA-10235; 8 pages.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/574,862	
			Filing Date	April 6, 2006	
			First Named Inventor	Michael J. Pugia	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
			Attorney Docket Number	017191.0049	
Sheet	2	of	7		

		Jortani et al.; "Sensitive Noninvasive Marker for the Diagnosis of Probable Bacterial or Viral Infection," <i>Journal of Clinical Laboratory Analysis</i> , Vol. 18 (2004) pp. 289-295.	
		Pugia et al.; "The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections," <i>Clinica Chimica Acta</i> , Vol. 341 (2004) pp. 73-81.	
		Suzuki et al.; "Suppression of Invasion and Peritoneal Carcinomatosis of Ovarian Cancer Cell Line by Overexpression of Bikunin," <i>Int. J. Cancer</i> , Vol. 104, pp. 289-302, (2003).	
		Capon et al.; "In acute inflammation, the chondroitin-4 sulphate carried by bikunin is not only longer; it is also undersulphated," <i>Biochimie</i> , Vol. 85 (2003) pp. 101-107.	
		Kobayashi et al.; "Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade," <i>Eur. J. Biochem.</i> , Vol. 269, pp. 3945-3957 (2002).	
		Mizon et al.; "Urinary Bikunin Determination Provides Insight into Proteinase/Proteinase Inhibitor Imbalance in Patients with Inflammatory Diseases," <i>Clin Chem Lab Med</i> 2002, Vol. 40(6), pp. 579-586, 2002.	
		Kreft et al.; "Polarized Expression of Tamm-Horsfall Protein by Renal Tubular Epithelial Cells Activates Human Granulocytes," <i>Injection and Immunity</i> , May 2002, pp. 2650-2656.	
		Suzuki et al.; "Kunitz-type Protease Inhibitor Bikunin Disrupts Phorbol Ester-induced Oligomerization of CD44 Variant Isoforms Containing Epitope v9 and Subsequently Suppresses Expression of Urokinase-type Plasminogen Activator in Human Chondrosarcoma Cells," <i>The Journal of Biological Chemistry</i> , Vol. 277 (10), March 8, 2002, pp. 8022-8032.	
		Matsumi et al.; "Changes in Urinary Trypsin Inhibitor in Blood and Urine, as Well as Serum Cytokines in Living Related Liver Transplantation," <i>Department of Anesthesiology and Resuscitology, Ikeyama University Graduate School of Medicine and Dentistry, Okayama 700-8558</i> , September 12, 2002, 12 pages.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/574,862
				Filing Date	April 6, 2006
				First Named Inventor	Michael J. Pugia
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	7	Attorney Docket Number	017191.0049

		Isogai et al.; "Quantitative analysis of bikunin-laden mast cells in follicular eruptions and chronic skin lesions of atopic dermatitis," <i>Arch Dermatol Res</i> , (2002) Vol. 294, pp. 387-392.	
		Tyagi et al.; "The Liver-Specific Human α_1 -Microglobulin/Bikunin Precursor (AMBP) is Capable of Self-Association," <i>Archives of Biochemistry and Biophysics</i> , Vol. 399 (1), March 1, 2002, pp. 66-72.	
		Sugita et al.; "Effect of a human urinary protease inhibitor (Ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass," <i>J. Cardiovasc Surg.</i> , Vol. 43(4), pp. 437-44.	
		Lin et al.; "Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis," <i>Journal of Gastroenterology and Hepatology</i> , Vol. 17, pp. 140-147; 2002.	
		Pugia et al.; "Clinical utility of a rapid test for uristatin," <i>Clinical Biochemistry</i> , Vol. 32, pp. 105-110, 2002..	
		Moriyama et al.; "Expression of Inter- α Inhibitor Related Proteins in Kidneys and Urine of Hyperoxaluric Rats," <i>The Journal of Urology</i> , Vol. 165, pp. 1687-1692, May 2001.	
		Takubo et al.; "Urinary trypsin inhibitor levels in the urine of patients with haematological malignancies," <i>Haematologia</i> , Vol. 31 (3), pp. 267-272 (2001).	
		Suzuki et al.; "Excretion of Bikunin and Its Fragments in the Urine of Patients with Renal Stones," <i>The Journal of Urology</i> , Vol. 166, pp. 268-274, July 2001.	
		Janssen et al.; "Expression of inter- α -trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells," <i>Kidney International</i> , Vol. 60, pp. 126-136, 2001.	
		Mizon et al.; "The chondroitin sulfate chain of bikunin-containing proteins in the inter- α -inhibitor family increases in size in inflammatory diseases," <i>Eur. J. Biochem</i> , Vol. 268, pp. 2217-2724, 2001.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/574,862		
		Filing Date	April 6, 2006		
		First Named Inventor	Michael J. Pugia		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	4	of	7	Attorney Docket Number	017191.0049

		Suzuki et al.; "Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins," <i>Biochimica et Biophysica Acta</i> , pp. 26-36, 2001.	
		Kobayashi et al.; "Identity of Urinary Trypsin Inhibitor-binding Protein to Link Protein," <i>The Journal of Biological Chemistry</i> , Vol. 275 (28), pp. 21185-21191, July 14, 2000.	
		Thuveson et al.; "The Low pH in Trans-Golgi Triggers Autocatalytic Cleavage of Pre- α -inhibitor Heavy Chain Precursor," <i>The Journal of Biological Chemistry</i> , Vol. 275 (40), pp. 30996-31000, October 6, 2000.	
		Mizon et al.; "Human pre- α -inhibitor is a positive acute-phase protein that is more susceptible than inter- α -inhibitor to proteolysis by stimulated neutrophils," <i>European Journal of Clinical Investigation</i> , Vol. 30, pp. 79-86, 2000.	
		Dean et al.; "Effects of inter- α -inhibitor and several of its derivatives on calcium oxalate crystallization <i>in vitro</i> ," <i>Clinical Science</i> , Vol. 98, pp. 471-480, 2000.	
		Balduyck et al.; "Inflammation-induced systemic proteolysis of inter- α -inhibitor in plasma from patients with sepsis," <i>J. Lab Clin Med</i> , Vol. 135 (2), pp. 188-198, February 2000.	
		Fries et al.; "Bikunin – not just a plasma proteinase inhibitor," <i>The International Journal of Biochemistry & Cell Biology</i> , Vol. 32, pp. 125-137, 2000.	
		Iida et al.; "Expression of Bikunin mRNA in Renal Epithelial Cells After Oxalate Exposure," <i>The Journal of Urology</i> , Vol. 162, pp. 1480-1486, October 1999.	
		Marengo et al.; "Differential Expression of Urinary Inter- α -Trypsin Inhibitor Trimers and Dimers in Normal Compared to Active Calcium Oxalate Stone Forming Men," <i>The Journal of Urology</i> , Vol. 159, pp. 1444-1450, May 1998.	
		Bost et al.; "Intera- α -trypsin inhibitor proteoglycan family, A group of proteins binding and stabilizing the extracellular matrix," <i>Eur. J. Biochem</i> , Vol. 252, pp. 339-346, 1998.	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/574,862
				Filing Date	April 6, 2006
				First Named Inventor	Michael J. Pugia
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	7	Attorney Docket Number	017191.0049

		Dawson et al.; "Inter- α -inhibitor in calcium stones," <i>Clinical Science</i> , Vol. 95, pp. 187-193, 1998.	
		Mizon et al.; "Human pre-a-inhibitor: isolation from a by-product of industrial scale plasma fractionation and structural analysis of its H3 heavy chain," <i>Journal of Chromatography B</i> , Vol. 692, pp. 281-291, 1997.	
		Marlor et al.; "Identification and Cloning of Human Placental Bikunin, a Novel Serine Protease Inhibitor Containing Two Kunitz Domains," <i>The Journal of Biological Chemistry</i> , Vol. 272 (18), pp. 122202-122208, May 2, 1997.	
		Delaria et al.; "Characterization of Placental Bikunin, a Novel Human Serine Protease Inhibitor," <i>The Journal of Biological Chemistry</i> , Vol. 272 (18), pp. 12209-12214, May 2, 1997.	
		Kyoto Daiichi Kagaku Co., Ltd. Development and Production Division; "Technical Data On Methods of Measuring Urinary Trypsin Inhibitor (UTI) (Enzyme Inhibition Method)," February 25, 1997, 28 pages.	
		Yamasaki et al.; "Uptake of human urinary trypsin inhibitor by the kidney epithelial cell line, LLC-PK ₁ ," <i>Eur J Physiol</i> , Vol. 433, pp. 9-15, 1996.	
		Salier et al.; "The inter- α -inhibitor family: from structure to regulation," <i>Biochem J</i> , Vol. 315, pp. 1-9, 1996.	
		Heron et al.; "Involvement of the three inter- α -trypsin inhibitor (ITI) heavy chains in each member of the serum ITI family," <i>FEBS Letters</i> , Vol. 374, pp. 195-198, 1995.	
		Maradny et al.; "Urinary trypsin inhibitor may have a protective effect on endothelial cells in preeclampsia," <i>Acta Obstet Gynecol Scand</i> , Vol. 73, pp. 755-757, 1994.	
		Takemura et al.; "A Clinical Study of Urinary Trypsin Inhibitor, an Acute Phase Reactant in Urine, In Acute Pediatric Infectious Diseases," <i>Japanese Journal of Inflammation</i> , Vol. 14 (1), pp. 53-57, January 1994.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/574,862		
		Filing Date	April 6, 2006		
		First Named Inventor	Michael J. Pugia		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	6	of	7	Attorney Docket Number	017191.0049

		Takemura et al.; "Acute-Phase Reactants in Urine: A Clinical Investigation of Urinary Trypsin Inhibitor in Pediatric Infectious Diseases," 108-494	
		Article: Belova et al.; <i>Biokhimiia</i> , Vol. 58(8), pp. 1199-11205, August 1993	
		Daveau et al.; "Human inter- α -inhibitor family in inflammation: simultaneous synthesis of positive and negative acute-phase proteins," <i>Biochem J.</i> , Vol. 292, pp. 485-492, 1993.	
		Noda, Tadafumi; "The Immunochemical Assay of Human Urinary Trypsin Indicator and Its Clinical Significance As an Acute-Phase Reactant," <i>Journal of the Osaka City Medical Center</i> , Vol. 41(2), pp. 489-500, June 1992.	
		Rourt et al.; "Electrophoretic Pattern of the Inter- α -Inhibitor Family Proteins in Human Serum, Characterized by Chain-Specific Antibodies," <i>Biol. Chem. Hoppe-Seyler</i> , Vol. 373, pp. 1019-1024, October 1992.	
		Piette et al.; "Urinary Trypsin Inhibitory Activity for the Diagnosis of Bacterial Infection: A Prospective Study in 690 Patients," <i>EJM</i> , Vol. 1 (5), pp. 273-276, September 1992.	
		Trefz et al.; "Establishment of an Enzyme-Linked Immuno-Sorbent Assay for Urinary Trypsin Inhibitor by Using a Monoclonal Antibody," <i>Journal of Immunoassay</i> , Vol. 12(3), pp. 347-369, 1991.	
		Kuwajima et al.; "Automated Measurement of Trypsin Inhibitor in Urine with a Centrifugal Analyzer: Comparison with Other Acute Phase Reactants," <i>Clin Biochem</i> , Vol. 23, pp. 167-171, 1990.	
		Article: Nishino et al.; "Measurement of urinary trypsin inhibitor in urine, plasma and cancer tissues of patients with stomach cancer," <i>Haemostasis</i> , Vol. 19(2), pp. 112-119, 1989.	
		Pratt et al.; "Inflammatory Cells Degrade Inter- α Inhibitor to Liberate Urinary Proteinase Inhibitors," <i>Journal of Leukocyte Biology</i> , Vol. 45, pp. 1-9, 1989.	
		Loutfti et al.; "Urinary Trypsin Inhibitory Capacity and α_1 Protease Inhibitor," <i>Ann. Biol. Clin.</i> , Vol. 47, pp. 261-267, 1989.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/574,862		
		Filing Date	April 6, 2006		
		First Named Inventor	Michael J. Pugia		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	7	of	7	Attorney Docket Number	017191.0049

		Kaumeyer et al.; "The mRNA for a proteinase inhibitor related to the HI-30 domain of inter- α -trypsin inhibitor also encodes α -1-microglobulin (protein HC)," <i>Nucleic Acids Research</i> , Vol. 14 (20), pp. 7839-7850, 1986.	
		Hochstrasser et al.; "Kunitz-Type Proteinase Inhibitors Derived by Limited Proteolysis of the Inter- α -Trypsin Inhibitor, V ^[1-4] ," <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , Vol. 362, pp. 1357-1362, October 1981.	
		Friedman, Theodore; "Further Characterization of the Subunit of Tamm-Horsfall Mucoprotein," <i>Biochimica et Biophysica Acta</i> , Vol. 130, pp. 355-360, 1966.	
		Dehne et al.; "Tamm-Horsfall Protein, α_1 - and β_2 -Microglobulins as Micromolecular Markers of Renal Function in Cardiac Surgery," <i>Anaesthetist</i> , Vol. 44, pp. 545-551, 1995.	
		Pfleiderer et al.; "Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of α_1 -microglobulin and Tamm-Horsfall protein," <i>Clin Investig</i> , Vol. 71, pp. 972-977, 1993.	
		Rosenmann et al.; "Tissue antigens in normal and pathologic urine samples: A review," <i>Kidney International</i> , Vol. 16, pp. 337-344, 1979.	
		Article: Faarvang, Hans Jorgen; "Urinary Trypsin Inhibitor in Man ("Mingin")," Munksgaard, Copenhagen, 1965, 37 pages.	
		Dillard et al.; "The Trypsin Inhibitor of the Urine in Health and Disease," <i>Biochemical Laboratory, Medical School, University of Virginia</i> , pp. 266-271, April 24, 1950.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.